1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €5.17 (-26.98%). The median is €5.17 (-26.98%).
| Buy |
4 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 19.91M | 14.77% |
| Gross profit | 11.07M | 25.77% |
| Net profit | -2.55M | 31.70% |
| EBITDA | 951.56K | 623.59% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €31.32M |
Number of shares | 4.51M |
52-week high/low | €8.10 - €3.27 |
| Dividends | No |
Beta | 1.49 |
P/E ratio | -3.47 |
PEG ratio | -0.05 |
P/B ratio | 4.92 |
P/S ratio | 0.41 |
Company profile
| Name | Harvard Bioscience |
| CEO | John D. Duke |
| Employees | 328 |
Deep Dive
Discover assets
Shareholders of Harvard Bioscience also invest in the following assets
